Key result
The P2Y1 receptor exhibits constitutive Gq protein signaling and β-arrestin 2 recruitment in human platelets and HEK293T cells, which is abolished by the inverse agonists MRS2179, MRS2279, and MRS2500.
Why the study?
P2Y1 receptor inhibition may provide efficient platelet inhibition with minimal bleeding risk, making accurate characterization of P2Y1 receptor antagonists an important preliminary step.
P2Y1 receptors exhibit constitutive activity in human platelets, and specific antagonists act as inverse agonists, highlighting a potential novel target for antiplatelet therapy.
May support P2Y1-R inverse agonism for antiplatelet effects; hypothesis-generating in animal models and requires human validation.
Background Purinergic P2Y 1 and P2Y 12 receptors (P2Y 1 -R and P2Y 12 -R) are G protein-coupled receptors (GPCR) activated by adenosine diphosphate (ADP) to mediate platelet activation, thereby playing a pivotal role in hemostasis and thrombosis. While P2Y 12 -R is the major target of antiplatelet drugs, no P2Y 1 -R antagonist has yet been developed for clinical use. However, accumulating data suggest that P2Y 1 -R inhibition would ensure efficient platelet inhibition with minimal effects on bleeding. In this context, an accurate characterization of P2Y 1 -R antagonists constitutes an important preliminary step. Results Here, we investigated the pharmacology of P2Y 1 -R signaling through Gq and β-arrestin pathways in HEK293T cells and in mouse and human platelets using highly sensitive resonance energy transfer-based technologies (BRET/HTRF). We demonstrated that at basal state, in the absence of agonist ligand, P2Y 1 -R activates Gq protein signaling in HEK293T cells and in mouse and human platelets, indicating that P2Y 1 -R is constitutively active in physiological conditions. We showed that P2Y 1 -R also promotes constitutive recruitment of β-arrestin 2 in HEK293T cells. Moreover, the P2Y 1 -R antagonists MRS2179, MRS2279 and MRS2500 abolished the receptor dependent-constitutive activation, thus behaving as inverse agonists. Conclusions This study sheds new light on P2Y 1 -R pharmacology, highlighting for the first time the existence of a constitutively active P2Y 1 -R population in human platelets. Given the recent interest of P2Y 12 -R constitutive activity in patients with diabetes, this study suggests that modification of constitutive P2Y 1 -R signaling might be involved in pathological conditions, including bleeding syndrome or high susceptibility to thrombotic risk. Thus, targeting platelet P2Y 1 -R constitutive activation might be a promising and powerful strategy for future antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Ribes et al. (2023) studied this question. P2Y1-R antagonists (MRS2179, MRS2279, MRS2500) vs. Basal state / vehicle was evaluated on Constitutive Gq protein signaling and β-arrestin 2 recruitment. The P2Y1 receptor exhibits constitutive Gq protein signaling and β-arrestin 2 recruitment in human platelets and HEK293T cells, which is abolished by the inverse agonists MRS2179, MRS2279, and MRS2500.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: